LGM Pharma is a Pixantrone Maleate 144675-97-8 active pharmaceutical ingredient supplier distributor, based in the USA.
Questions? Call our customer API support number 1-(800)-881-8210.
LGM Pharma offers this active ingredient but not the finished dosage forms.Inquire about Pixantrone Maleate
|Molecular Weight:||557.52 g/mol|
|Assay/Purity:||Typically NLT 98%|
Pixantrone Maleate News:
Pixantrone maleate, CAS Number 146675-97-8, is an anthracenedione anthracycline derivative, developed by Cell Therapeutics Incorporated. Pixantrone maleate is used for treatment of patients with non-Hodgkin's lymphoma. LGM Pharma is a provider of pixantrone maleate for research and development purposes.
As a promising treatment for aggressive non-Hodgkin's lymphoma, pixantrone maleate is well tolerated when substituted for anthracyclines in combination regimens, and shows comparable rates of complete remission. Pixantrone is similar in structure to the anthracenedione mitoxantrone, however it lacks the 5,8-dihydroxy substitution groups, which is found in mitoxanthrone. Mitoxanthrone was shown in studies to induce the rates of patient cardiotoxicity in patients. A trial, deemed PIX301 phase III, used pixantrone maleate as a single-agent for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. For this trial randomized patients received either pixantrone or another single agent of the investigators' choice. Positive results were found, showing the rate of confirmed and unconfirmed remissions in patients treated with pixantrone was significantly higher than in those patients who received other agents. The overall response rate and progression-free survival in patients in the trial were also demonstrated in the PIX301 phase lll trial. Another study, phase III PIX302, treated patients with indolent non-Hodgkin's lymphomas, and combined pixantrone and rituximab in treatment. Trials found this combination to be superior to rituximab used alone in patients with relapsed or refractory disease. Evidence in all trials also shows that pixantrone maleate is well tolerated when substituted for anthracyclines in combination regimens for aggressive non-Hodgkin's lymphoma .&nbsp; The United States Food and Drug Administration is in the process of considering pixantrone for use in adult patients with relapsed or refractory aggressive non-Hodgkin's lymphoma, as well as and indolent non-Hodgkin's lymphoma, on a fast-track basis. LGM Pharma can work with its clients through all research stages, clinical trials, development phases, regulatory documentation submission and up till commercialization of the pixantrone maleate product.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1).
Any patent infringement and resulting liability is solely at buyer risk.